Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade.
bilirubin
biomarkers
hepatocellular carcinoma
immunotherapy
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Jul 2020
10 Jul 2020
Historique:
received:
18
06
2020
accepted:
07
07
2020
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
16
7
2020
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICI) have shown positive results in patients with hepatocellular carcinoma (HCC). As liver function contributes to prognosis, its precise assessment is necessary for the safe prescribing and clinical development of ICI in HCC. We tested the accuracy of the albumin-bilirubin (ALBI) grade as an alternative prognostic biomarker to the Child-Turcotte-Pugh (CTP). In a prospectively maintained multi-centre dataset of HCC patients, we assessed safety and efficacy of ICI across varying levels of liver dysfunction described by CTP (A to C) and ALBI grade and evaluated uni- and multi-variable predictors of overall (OS) and post-immunotherapy survival (PIOS). We studied 341 patients treated with programmed-death pathway inhibitors (
Identifiants
pubmed: 32664319
pii: cancers12071862
doi: 10.3390/cancers12071862
pmc: PMC7408648
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : PS3416
Pays : United Kingdom
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
J Hepatol. 2019 Dec;71(6):1175-1183
pubmed: 31449860
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
J Hepatol. 2005;42 Suppl(1):S100-7
pubmed: 15777564
J Gastroenterol Hepatol. 2016 Jul;31(7):1300-6
pubmed: 26751608
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Therap Adv Gastroenterol. 2016 Mar;9(2):240-9
pubmed: 26929785
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
Dig Dis. 2014;32(6):711-6
pubmed: 25376288
Cancers (Basel). 2020 Jan 11;12(1):
pubmed: 31940757
Liver Int. 2017 Mar;37(3):423-433
pubmed: 27566596
Liver Int. 2018 Feb;38(2):321-330
pubmed: 28736952
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Transplant Proc. 2019 Dec;51(10):3338-3346
pubmed: 31732203
J Oncol Pract. 2017 Jun;13(6):356-364
pubmed: 28605614
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Cancer. 2019 Sep 15;125(18):3234-3241
pubmed: 31154669
J Gastroenterol Hepatol. 2017 Dec;32(12):1975-1981
pubmed: 28295594
Hepat Oncol. 2016 Aug;3(3):201-211
pubmed: 30191042
Cancer Treat Rev. 2018 Jul;68:16-24
pubmed: 29783126
Oncoimmunology. 2012 Jan 1;1(1):48-55
pubmed: 22720211
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
Am J Gastroenterol. 2016 Aug;111(8):1208-9
pubmed: 27481429
Aliment Pharmacol Ther. 2017 Mar;45(5):714-722
pubmed: 28116800
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Liver Int. 2009 Apr;29(4):502-10
pubmed: 19141028
Lancet Oncol. 2017 Feb;18(2):e101-e112
pubmed: 28214411
Immunology. 2020 Feb;159(2):167-177
pubmed: 31646612
Hepatology. 2019 May;69(5):2258-2270
pubmed: 30382576
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Am J Clin Oncol. 2018 Sep;41(9):861-866
pubmed: 28418940
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
J Hepatol. 2018 Aug;69(2):353-358
pubmed: 29704513
J Hepatol. 2017 Feb;66(2):338-346
pubmed: 27677714
Oncogene. 2020 Apr;39(18):3620-3637
pubmed: 32157213
Cancers (Basel). 2019 Jul 07;11(7):
pubmed: 31284682
J Hepatol. 2020 Feb;72(2):342-352
pubmed: 31954496